Article PDF
Avoid common mistakes on your manuscript.
References
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR and Gallinger S (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15): 1960–1966
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT and Saijo N (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R and Wu YL (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652): 1809–1818
Pirker R, Pereira JR, Szczesna A, Von Pawel J, Krzakowski M and Ramlau R (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674): 1525–1531
Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol, 5(7): 378–391, 2008.
Ruegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K and Stupp R. (2003). The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 3(8): 673–691
Pircher A, Heidegger I, Gunsilius E and Hilbe W. (2010). Biomarkers of angiogenic and their role in clinical oncology.. memo 3: 27–32
Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1): 39–51
Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F and Kramar A. (2008). Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 26(22): 3721–3726
Fridrik M. (2010). Qualitative and quantitative assessment of endpoints in clinical trials.. memo 3: 33–36
Ratain MJ and Sargant DJ. (2009). Optimising the design of phase II oncology trial: the importance of randomisation. Eur J Cancer 45: 275–280
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hilbe, W. Changing paradigms in clinical trials. memo 3, 1–2 (2010). https://doi.org/10.1007/s12254-010-0180-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-010-0180-0